- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of April 30
The Center for Biosimilars® recaps the top 5 articles for the week of April 30, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 30.
Number 5: Real-world evidence shows that biosimilar filgrastim has the potential to improve access to febrile neutropenia prophylaxis.
Number 4: A session at the Academy of Managed Care Pharmacy’s Managed Care & Specialty Pharmacy Annual Meeting in Boston, Massachusetts, provided an in-depth look at state legislation on biosimilars.
Number 3: Biosimilar developer Biocon has been issued a new Form 483 noting observations from an FDA inspection of its Bangalore manufacturing facility.
Number 2: Celltrion’s trastuzumab biosimilar, Herzuma, has launched in Europe, making it the second biosimilar referencing Herceptin to become available in the European marketplace.
Number 1: The FDA has issued a Complete Response Letter for Sandoz’s proposed rituximab biosimilar.
Finally, last week, our e-newsletter asked whether you think that physician education on biosimilars will improve as more products come to market.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
